Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Fougera Pharmaceuticals Articles

US FTC puts conditions on Novartis buy of Fougera

17 July 2012

Novartis to buy US generic derma company Fougera for over $1.5 billion

3 May 2012

Protherics falls deeper into loss in fiscal 2007/8

16 June 2008

Nycomed completes $346M Bradley buy

3 March 2008

Nycomed bids $346M for USA's Bradley

5 November 2007

Protherics upbeat despite higher losses

18 December 2006

Protherics: healthy cash flow after CytoFab deal

17 April 2006

Fougera's CroFab celebrates 5th anniversary

22 August 2005

Texas sues 12 firms over drug prices

16 May 2005

Fougera debuts to new ophthalmics

24 January 2005

Fougera gets first clearance for ciclopirox cream

10 January 2005

Altana unit gets OK for generic Diprolene AF in USA

27 January 2003

Fougera first to market generic clindamycin lotion

11 February 2002

ALTANA APPOINTMENT

20 June 1994

Showing 1-14 of 14 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS